CA2185661A1 - Novel iron chelator and inhibitor of iron-mediated oxidation - Google Patents
Novel iron chelator and inhibitor of iron-mediated oxidationInfo
- Publication number
- CA2185661A1 CA2185661A1 CA002185661A CA2185661A CA2185661A1 CA 2185661 A1 CA2185661 A1 CA 2185661A1 CA 002185661 A CA002185661 A CA 002185661A CA 2185661 A CA2185661 A CA 2185661A CA 2185661 A1 CA2185661 A1 CA 2185661A1
- Authority
- CA
- Canada
- Prior art keywords
- iron
- exochelins
- inhibitor
- novel
- mediated oxidation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 title abstract 4
- 229910052742 iron Inorganic materials 0.000 title abstract 2
- 230000001404 mediated effect Effects 0.000 title abstract 2
- OEUUFNIKLCFNLN-LLVKDONJSA-N chembl432481 Chemical compound OC(=O)[C@@]1(C)CSC(C=2C(=CC(O)=CC=2)O)=N1 OEUUFNIKLCFNLN-LLVKDONJSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 230000003647 oxidation Effects 0.000 title 1
- 238000007254 oxidation reaction Methods 0.000 title 1
- 108010013932 exochelins Proteins 0.000 abstract 4
- 230000015572 biosynthetic process Effects 0.000 abstract 2
- 210000004165 myocardium Anatomy 0.000 abstract 2
- 150000003254 radicals Chemical class 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000010410 reperfusion Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Exochelins can be used to prevent damage to living tissue from the formation or presence of the (OH) radical. In particular, the invention is directed to the administration of exochelins to infarcted myocardium prior to or coincidental with reperfusion to prevent damage to myocardium from iron mediated free radical formation. Also presented is the chemical structure of exochelins and modified exochelins at well as other applications of these materials in the treatment and diagnosis of disease in mammals.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/383,180 | 1995-02-03 | ||
US08/383,180 US5721209A (en) | 1995-02-03 | 1995-02-03 | Iron chelator and inhibitor of iron-mediated oxidant injury |
PCT/IB1996/000171 WO1996023502A1 (en) | 1995-02-03 | 1996-01-26 | Novel iron chelator as inhibitor of iron-mediated oxidation |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2185661A1 true CA2185661A1 (en) | 1996-08-08 |
CA2185661C CA2185661C (en) | 2005-10-04 |
Family
ID=35395857
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002185661A Expired - Fee Related CA2185661C (en) | 1995-02-03 | 1996-01-26 | Novel iron chelator and inhibitor of iron-mediated oxidation |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2185661C (en) |
-
1996
- 1996-01-26 CA CA002185661A patent/CA2185661C/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2185661C (en) | 2005-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BG103438A (en) | Improvements of or in relation to diagnostic/therapeutical forms | |
AU4674496A (en) | Novel iron chelator and inhibitor of iron-mediated oxidation | |
CA2180950A1 (en) | Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof | |
TW369521B (en) | Androstenone derivative | |
BR9902243A (en) | Biomedical devices with hydrophilic coatings | |
RU94000061A (en) | Cholesterol esters and unsaturated fatty acids, the method of treatment and the pharmaceutical or cosmetic composition | |
ZA88798B (en) | Dental anti-plaque and anti-caries agent | |
EP2348032A3 (en) | 6.Alpha.,9.alpha.-difluoro-17.alpha.-'(2-furanylcarboxyl) oxy]-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothiotic acid s-fluoromethyl ester as an anti-inflammatory agent | |
FR2782269B1 (en) | COSMETIC AND / OR DERMATOLOGICAL COMPOSITION CONTAINING SALICYLIC ACID OR A SALICYLIC ACID DERIVATIVE AND USE THEREOF | |
CA2289717A1 (en) | Novel therapy for constipation | |
SE8903914D0 (en) | ORAL COMPOSITION FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASES | |
CA2163361A1 (en) | Therapeutic substituted guanidines | |
FR2378523A1 (en) | ACNE TREATMENT MEDICINE | |
JPS57128634A (en) | Elastase-containing compound increasing absorption | |
FR2718639B1 (en) | Cosmetic and / or dermatological composition containing a tri (alpha-hydroxyacylate) of glycerol as the only precursor of glycerol. | |
HUP0001014A2 (en) | Use of gastrointestinal lipase inhibitors | |
ATE374618T1 (en) | USE OF RECOMBINANT HUMAN UTEROGLOBIN FOR THE TREATMENT OF FIBROTIC DISEASES | |
ES2145302T3 (en) | WHITENING AGENT. | |
DE69331465D1 (en) | INTRAVENOUS SOLUTION THAT REDUCES PROTEIN AND WATER LOSS IN THE BODY | |
CA2304564A1 (en) | Basket with one or more moveable legs | |
CA2185661A1 (en) | Novel iron chelator and inhibitor of iron-mediated oxidation | |
CA2246236A1 (en) | Treatment and prevention of adverse effects of reactive oxygen species | |
CA2241825A1 (en) | New monofunctionalized edta, dtpa and ttha derivatives and their use in medical diagnosis and therapy | |
IT8721999A0 (en) | PROCEDURE FOR THE MANUFACTURE OF FLOOR OR WALL COATINGS WHICH PRESENT IMPROVED RESISTANCE TO SOILING AND THE PRODUCT OBTAINED. | |
NO20003108L (en) | Use of melatonin energetic ligands in the preparation of pharmaceutical compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |